This study is looking at the safety of a drug called RAD301 ([68Ga]-RAD301) in healthy volunteers and people with certain cancers, including pancreatic, non-small cell lung, esophageal, cervical, endometrial, or ovarian cancer. The researchers want to see how the body handles RAD301 and how much radiation it gives off. You would receive a single dose of RAD301 through an IV (intravenous) and have scans to track it. The study will also check for any side effects over four weeks. This is an early-stage study, and the enrollment status is currently unclear.

Study design

This is an early-stage, open-label study involving a single dose of RAD301. It plans to enroll 9 participants, including healthy volunteers and those with specific solid tumors.

What's involved

You would receive a single IV dose of RAD301. You would have vital signs, ECGs (heart tests), and blood tests before and two weeks after the dose, plus three whole-body PET-CT and PET scans.

Compensation

Not stated in the trial record.

Follow-up

Your safety and tolerability of RAD301 will be measured for four weeks after the dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.